Takeda appoint Marc Weeks to Digital Lead role
pharmafile | October 31, 2016 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Takeda, digital
Takeda UK have appointed Marc Weeks to the newly created role of digital lead. The creation of the role comes as Takeda UK & Ireland aims to push forward its digital strategy and initiatives. Takeda has ambition plans to go beyond developing mobile apps and websites, often most associated with the digital area, to become partners with external technology ventures with a range of business areas.
Marc Weeks graduated from the University of Hertfordshire with a BSc in Computer Science. He has ten years of experience working within digital communications. He began his career in the Communications Department at Heathrow during the building of Terminal 5, he then went on to work at Shire Pharmaceutical in a number of roles over the course of eight years.
Kruti Popat, Business Intelligence Director, said: “I am delighted to announce this exciting new appointment. With rich previous experience working on digital pharmaceutical projects, Marc will fill a knowledge gap at Takeda UK that is instrumental to the company achieving its aim of proving better health and a brighter future through innovation.”
On his appointment, Marc Weeks said: “I am very excited to be joining such a vibrant, fast changing and innovative company. I was drawn to Takeda because of its ambition and keen desire to transform the company and wider environment to the benefit of patients and customers. I see so much potential in the company for delivering innovative digital strategies, and it is fantastic that this is being driven by the Senior Leadership Team. I’m looking forward to the opportunities that lay ahead in this fast-moving space and working with my new colleagues.”
Related Content
Von Willebrand disease – increasing awareness and access to vital care
Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about …
Combination treatments: Takeda’s Implementation Framework and the broader landscape
Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …
Takeda presents positive results from trial of chronic kidney disease treatment
Takeda Pharmaceuticals has announced positive results from a proof-of-concept study of mezagitamab (TAK-079) to treat …
